Skip to main content
Clinical Trials/CTRI/2024/04/065928
CTRI/2024/04/065928
Not yet recruiting
未知

Prospective Randomized Controlled Trial to Assess the Comparative Efficacy of Midodrine and Tolvaptan Combination Versus Midodrine Therapy in Refractory Ascites in Cirrhotic Patients with Hyponatremia with blinded endpoint assessment.

Amrita School of pharmacy0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: K746- Other and unspecified cirrhosis ofliver
Sponsor
Amrita School of pharmacy
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Amrita School of pharmacy

Eligibility Criteria

Inclusion Criteria

  • Newly diagnosed refractory ascites patients as per the AASLD and EASL guidelines.
  • Definite history of cirrhosis with hyponatremia.
  • Consenting to follow\-up.
  • CHILD PUGH \- B/C cirrhosis.

Exclusion Criteria

  • AKI (S. creatinine 1\.5mg/dL) and kidney problems.
  • High risk varices.
  • Cerebrovascular accidents within 30 days before the study medication.
  • Acute symptomatic hyponatremia and pseudohyponatremia
  • Hypothyroidism.
  • Cerebrovascular accidents.
  • Multiple strokes.

Outcomes

Primary Outcomes

Not specified

Similar Trials